MARKET

CRBP

CRBP

Corbus Pharmaceu
NASDAQ
8.08
+0.25
+3.13%
Opening 15:28 01/06 EST
OPEN
7.83
PREV CLOSE
7.83
HIGH
8.14
LOW
7.83
VOLUME
111.41K
TURNOVER
--
52 WEEK HIGH
20.56
52 WEEK LOW
4.640
MARKET CAP
141.74M
P/E (TTM)
-1.4648
1D
5D
1M
3M
1Y
5Y
1D
Weekly Report: what happened at CRBP last week (1229-0102)?
Weekly Report · 1d ago
Corbus Pharmaceuticals Holdings Inc. Stock Slides 2.7%, Underperforms Peers
Dow Jones · 12/30/2025 21:32
Weekly Report: what happened at CRBP last week (1222-1226)?
Weekly Report · 12/29/2025 10:03
Corbus Pharmaceuticals Holdings Inc. Stock Advances 2.9%, Outperforms Peers
Dow Jones · 12/24/2025 21:32
Weekly Report: what happened at CRBP last week (1215-1219)?
Weekly Report · 12/22/2025 10:03
After-Hours Biotech Rally: Inspira, MediciNova, DiaMedica Therapeutics Among Gainers
NASDAQ · 12/19/2025 04:27
Corbus Pharmaceuticals Announces Retirement of Board Member Holmer
TipRanks · 12/18/2025 21:36
Corbus Pharmaceuticals Board Member Alan Holmer Resigns Effective December 31
Reuters · 12/18/2025 21:06
More
About CRBP
Corbus Pharmaceuticals Holdings, Inc. is an oncology and obesity company. The Company has a diversified portfolio and is committed to helping people defeat serious illness by bringing scientific approaches to well-understood biological pathways. The Company’s oncology pipeline comprises two experimental drugs targeting solid tumors: CRB-701, an antibody drug conjugate (ADC) that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload, and CRB-601, an anti-integrin monoclonal antibody that blocks the activation of TGFB expressed on cancer cells. CRB-701 is a monoclonal antibody attached to a monomethyl auristatin E (MMAE) cytotoxic payload using a proprietary linker technology. The pipeline also includes CRB-913, a highly peripherally restricted cannabinoid type-1 (CB1) receptor inverse agonist for the treatment of obesity. CB1 inverse agonism is a clinically validated mechanism to induce weight loss.

Webull offers Corbus Pharmaceuticals Holdings Inc stock information, including NASDAQ: CRBP real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, CRBP stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading CRBP stock methods without spending real money on the virtual paper trading platform.